Ascendis Pharma Nears EU Approval for Achondroplasia Drug TransCon CNP
Event summary
- CHMP recommends marketing authorization for TransCon CNP (navepegritide) in the EU for treating achondroplasia in children.
- Final EC decision expected in Q4 2026, with potential EU launch in Germany in Q1 2027.
- TransCon CNP is the only approved therapy providing continuous systemic exposure to active CNP over a weekly dosing interval.
- Drug was designated as an orphan medicine during development, with EMA reviewing its maintenance post-approval.
The big picture
Ascendis Pharma's TransCon CNP represents a significant advancement in treating achondroplasia, a rare genetic disorder affecting over 250,000 people worldwide. The positive CHMP opinion positions the drug for EU approval, following its U.S. approval earlier in 2026. This milestone aligns with Ascendis' Vision 2030 objectives, reinforcing its focus on growth disorder therapies. The drug's unique once-weekly administration and continuous exposure to active CNP could set a new standard in the treatment landscape.
What we're watching
- Regulatory Timing
- Whether the European Commission will meet its Q4 2026 deadline for the final decision on TransCon CNP.
- Market Penetration
- The pace at which Ascendis can launch and scale TransCon CNP in the EU, starting with Germany in Q1 2027.
- Competitive Positioning
- How TransCon CNP's differentiated profile will perform against existing and emerging therapies for achondroplasia.
Related topics